+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Thyroid Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Thyroid Cancer Drugs Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5460329
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Thyroid Cancer Drugs Market is projected to reach USD 1.13 Billion in 2026. It is expected to continue growing at a CAGR of 11.15%, reaching USD 2.14 Billion by 2032.

The thyroid cancer drugs market is being reshaped by rising diagnosis, longer survivorship, and rapid adoption of biomarker-directed therapies. IARC GLOBOCAN 2022 reported more than 820,000 new thyroid cancer cases worldwide and about 47,500 deaths, underscoring a large treated population despite generally favorable outcomes in early-stage disease.

Commercial demand is concentrated across differentiated thyroid cancer, radioiodine-refractory disease, medullary thyroid cancer, and anaplastic thyroid cancer. Growth is increasingly tied to targeted drugs such as multikinase inhibitors, RET inhibitors, NTRK inhibitors, BRAF/MEK combinations, and supportive endocrine therapy that improves disease control and quality of life.

Transformative Shifts in the Thyroid Cancer Treatment Landscape

The competitive landscape is shifting from broadly used systemic therapy toward precision oncology. Established agents such as lenvatinib, sorafenib, cabozantinib, and vandetanib remain important, while selective RET inhibitors, tumor-agnostic NTRK inhibitors, and BRAF/MEK therapy have raised expectations for response, tolerability, and molecular testing.

Clinical practice is also changing through earlier genomic profiling, multidisciplinary tumor boards, and more active management of adverse events linked to chronic oral therapies. Payers and providers are placing greater weight on real-world evidence, duration of response, and patient-reported outcomes as treatment pathways become more personalized.

Cumulative Impact of Artificial Intelligence on Thyroid Cancer Drugs

Artificial intelligence is adding cumulative value across the thyroid cancer drugs value chain rather than acting as a standalone solution. AI-enabled ultrasound interpretation, digital pathology, radiomics, and natural language processing can help identify suspicious nodules, extract clinical data, and flag patients who may benefit from molecular testing or clinical trial referral.

For manufacturers and health systems, AI supports trial feasibility, pharmacovigilance, adherence monitoring, and real-world evidence generation. The highest-impact use cases require validated datasets, transparent models, privacy safeguards, and alignment with regulatory expectations for clinical decision support.

Key Regional Insights Across Global Thyroid Cancer Drug Demand

North America remains a high-value region because of broad access to molecular diagnostics, specialty oncology networks, clinical trial participation, and faster uptake of FDA-approved targeted therapies. Europe benefits from ESMO-aligned clinical practice, centralized health technology assessment, and growing emphasis on value-based reimbursement, although access timing varies by country and payer pathway.

Asia-Pacific is a major volume opportunity, led by China, India, Japan, South Korea, and Australia, with demand supported by diagnosis rates, hospital capacity expansion, population-based screening in several settings, and local oncology investment. Latin America shows improving specialist care in Brazil and Mexico but continues to face public-sector access gaps, while the Middle East is supported by national cancer strategies and tertiary care investment. Africa remains shaped by uneven diagnostic infrastructure, oncology workforce availability, pathology capacity, and reimbursement constraints.

Key Group Insights for Thyroid Cancer Drug Commercialization

Within ASEAN, thyroid cancer drug adoption is expanding as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines improve oncology access, though molecular testing availability and reimbursement remain uneven. GCC markets benefit from government-funded specialty hospitals, national cancer programs, and rising adoption of advanced therapeutics in Saudi Arabia, the UAE, Qatar, and neighboring countries.

The European Union is defined by HTA scrutiny, biospecimen standards, pharmacovigilance requirements, and harmonized regulatory pathways, while BRICS countries offer large patient pools, rising oncology infrastructure, and increasing relevance of local manufacturing and domestic clinical research. G7 markets lead in innovation, clinical trial density, biomarker testing, and premium therapy uptake, and NATO-aligned countries provide resilient pharmaceutical supply chains across many advanced economies while supporting cross-border regulatory and procurement coordination.

Key Country Insights Shaping Thyroid Cancer Drug Adoption

The United States leads in innovation, guideline-driven biomarker testing, specialist referral pathways, and access to FDA-approved targeted drugs, while Canada emphasizes evidence-based reimbursement and provincial formulary decisions. Mexico and Brazil are important Latin American markets where private-sector uptake is generally faster than public access. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong specialist care, established cancer centers, and structured reimbursement review, while Russia remains more sensitive to local access, procurement dynamics, and domestic supply considerations.

China and India offer major scale, rising cancer infrastructure, expanding genomic testing capacity, and growing domestic oncology capabilities. Japan combines advanced diagnostics, high treatment standards, and mature reimbursement processes, while South Korea supports rapid adoption through strong hospital systems and molecular oncology expertise. Australia supports broad evidence-based oncology care through structured reimbursement, specialist networks, and established clinical guideline use.

Actionable Recommendations for Thyroid Cancer Drug Industry Leaders

Industry leaders should prioritize broad molecular testing for RET, NTRK, BRAF, RAS, and other actionable alterations in appropriate patients, supported by companion diagnostics, pathologist engagement, and clinician education. Portfolio strategies should balance established multikinase inhibitors with precision therapies that address smaller but high-value biomarker-defined populations.

Commercial success depends on market access evidence, adverse-event management programs, patient adherence support, and region-specific affordability models. Companies should also invest in real-world registries, AI governance, decentralized trial capabilities, and partnerships with cancer centers to improve recruitment, evidence generation, and continuity of care.

Research Methodology for Evidence-Based Market Insights

This executive summary is based on triangulation of publicly available, authoritative sources, including WHO/IARC GLOBOCAN cancer statistics, FDA and EMA drug approval information, NCCN and ESMO treatment guidance, clinical trial registries, peer-reviewed oncology literature, and health technology assessment patterns.

The methodology emphasizes verified disease burden indicators, approved treatment classes, regional healthcare infrastructure, reimbursement dynamics, diagnostic availability, and observable adoption trends. Insights were synthesized to support strategic planning while avoiding unsupported market-size claims, market-share assumptions, or speculative forecasts.

Conclusion: Precision Medicine Defines the Next Growth Phase

The thyroid cancer drugs market is moving toward precision-led, evidence-driven care. While many patients with localized thyroid cancer have favorable outcomes, advanced, metastatic, radioiodine-refractory, medullary, and anaplastic disease continue to create strong demand for innovative systemic therapies.

Future market leadership will be shaped by biomarker testing, differentiated clinical evidence, equitable access, and disciplined use of AI-enabled tools. Organizations that combine scientific depth with regional access strategies are better positioned to support sustainable growth and improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Thyroid Cancer Drugs Market, by Cancer Type
7.1. Introduction
7.2. Anaplastic Thyroid Cancer (ATC)
7.3. Follicular Thyroid Cancer (FTC)
7.4. Hürthle Cell Carcinoma
7.5. Medullary Thyroid Cancer (MTC)
7.6. Papillary Thyroid Cancer (PTC)
8. Thyroid Cancer Drugs Market, by Treatment Modality
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Radioiodine Therapy
8.5. Surgery
8.6. Targeted Multikinase Therapy
8.7. Thyroid Stimulating Hormone (TSH) Suppression Therapy
9. Thyroid Cancer Drugs Market, by Drug Type
9.1. Introduction
9.2. Chemotherapy Agents
9.3. Hormone Therapy Drugs
9.4. Immunotherapy Drugs
9.5. Targeted Therapy Drugs
10. Thyroid Cancer Drugs Market, by Mode Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Pre-Filled Syringes
10.2.2. Vials
10.3. Oral
10.3.1. Capsules
10.3.2. Tablets
11. Thyroid Cancer Drugs Market, by Patient Age Group
11.1. Introduction
11.2. Pediatric
11.3. Adult
11.4. Geriatric
12. Thyroid Cancer Drugs Market, by Brand Status
12.1. Introduction
12.2. Branded
12.3. Generic
13. Thyroid Cancer Drugs Market, by End User
13.1. Introduction
13.2. Homecare Settings
13.3. Hospitals
13.4. Oncology Clinics
13.5. Research Organizations
14. Thyroid Cancer Drugs Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Thyroid Cancer Drugs Market, by Group
15.1. NATO
15.2. G7
15.3. BRICS
15.4. European Union
15.5. ASEAN
15.6. GCC
16. Thyroid Cancer Drugs Market, by Country
16.1. China
16.2. United States
16.3. Japan
16.4. India
16.5. Germany
16.6. United Kingdom
16.7. Australia
16.8. France
16.9. South Korea
16.10. Italy
16.11. Canada
16.12. Russia
16.13. Brazil
16.14. Mexico
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Ltd.
18.2. AbbVie Inc.
18.3. Amgen Inc.
18.4. Aprazer Healthcare Pvt Ltd.
18.5. AstraZeneca PLC
18.6. Bayer AG
18.7. Biovista Inc.
18.8. Blueprint Medicines Corporation
18.9. Bristol-Myers Squibb Company
18.10. Cellectar Biosciences, Inc.
18.11. Dr Reddy's Laboratories Ltd.
18.12. Eisai Co., Ltd.
18.13. Eli Lilly and Company
18.14. Exelixis, Inc.
18.15. Genentech, Inc
18.16. GlaxoSmithKline PLC
18.17. Glenmark Pharmaceuticals Ltd.
18.18. Hetero Healthcare Limited
18.19. Ipsen SA
18.20. Janssen Pharmaceuticals, Inc.
18.21. Lupin Limited
18.22. Merck & Co., Inc.
18.23. MSN Laboratories
18.24. Natco Pharma Ltd.
18.25. Novartis AG
18.26. Pfizer Inc.
18.27. Roche Holding AG
18.28. Sanofi S.A.
18.29. Takeda Pharmaceutical Company Limited
18.30. Teva Pharmaceutical Industries Ltd
18.31. Vascular Biogenics Ltd.
18.32. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL THYROID CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANAPLASTIC THYROID CANCER (ATC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANAPLASTIC THYROID CANCER (ATC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANAPLASTIC THYROID CANCER (ATC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FOLLICULAR THYROID CANCER (FTC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FOLLICULAR THYROID CANCER (FTC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FOLLICULAR THYROID CANCER (FTC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HÜRTHLE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HÜRTHLE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HÜRTHLE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MEDULLARY THYROID CANCER (MTC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MEDULLARY THYROID CANCER (MTC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MEDULLARY THYROID CANCER (MTC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PAPILLARY THYROID CANCER (PTC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PAPILLARY THYROID CANCER (PTC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PAPILLARY THYROID CANCER (PTC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RADIOIODINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RADIOIODINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RADIOIODINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TARGETED MULTIKINASE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TARGETED MULTIKINASE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TARGETED MULTIKINASE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HORMONE THERAPY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HORMONE THERAPY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HORMONE THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TARGETED THERAPY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TARGETED THERAPY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TARGETED THERAPY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PRE-FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 113. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 114. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 115. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 118. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 120. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 144. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 147. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 148. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 149. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 150. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. NATO THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. NATO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 164. NATO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 165. NATO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 166. NATO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 167. NATO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 168. NATO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 169. NATO THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 170. NATO THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 171. NATO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. G7 THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. G7 THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 174. G7 THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 175. G7 THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 176. G7 THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. G7 THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 178. G7 THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 179. G7 THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. G7 THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 181. G7 THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. BRICS THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. BRICS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 184. BRICS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 185. BRICS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 186. BRICS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. BRICS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 188. BRICS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 189. BRICS THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. BRICS THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 191. BRICS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 204. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 205. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 206. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 208. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 209. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 210. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 211. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. GCC THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. GCC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 214. GCC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 215. GCC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 216. GCC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 217. GCC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 218. GCC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 219. GCC THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 220. GCC THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 221. GCC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 223. CHINA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 225. CHINA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 226. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 227. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 228. CHINA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 229. CHINA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 230. CHINA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 231. CHINA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 232. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. JAPAN THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 245. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 246. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 249. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 250. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 251. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 252. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. INDIA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. INDIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 255. INDIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 256. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 257. INDIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. INDIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 259. INDIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 260. INDIA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. INDIA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 262. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. GERMANY THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 265. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 266. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 268. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 270. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 271. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 272. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. FRANCE THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 295. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 296. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 299. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 300. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 301. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 302. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. ITALY THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 315. ITALY THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 316. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 317. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. ITALY THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 319. ITALY THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 320. ITALY THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 321. ITALY THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 322. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. CANADA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 325. CANADA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 326. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 327. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 328. CANADA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 329. CANADA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 330. CANADA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 331. CANADA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 332. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. RUSSIA THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 335. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 336. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 337. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 338. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 339. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 340. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 341. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 342. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. BRAZIL THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 344. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 347. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 348. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 349. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 350. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 351. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY BRAND STATUS, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 353. MEXICO THYROID CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 354. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 355. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 356. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 357. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 358. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 359. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 360. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 361. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY BRAN

Companies Mentioned

  • Abbott Ltd.
  • AbbVie Inc.
  • Amgen Inc.
  • Aprazer Healthcare Pvt Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Biovista Inc.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences, Inc.
  • Dr Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Healthcare Limited
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • MSN Laboratories
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Vascular Biogenics Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.13 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.14 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Follicular Thyroid Cancer Drugs Market - Global Strategic Business Report - Product Image

Follicular Thyroid Cancer Drugs Market - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Hurthle Cell Carcinoma Treatment Market - Global Forecast 2026-2032 - Product Image

Hurthle Cell Carcinoma Treatment Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Thyroid Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Thyroid Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Thyroid Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Thyroid Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Follicular Thyroid Cancer Drug Sales Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Follicular Thyroid Cancer Drug Sales Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From

About the Thyroid Cancer Drugs Market

The Thyroid Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat thyroid cancer. These drugs are used to reduce the size of tumors, reduce the risk of recurrence, and improve the quality of life for those affected by the disease. Commonly used drugs include radioactive iodine, tyrosine kinase inhibitors, and monoclonal antibodies. The market is highly competitive, with many companies vying for a share of the market. Major players include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. These companies are constantly researching and developing new drugs to improve the treatment of thyroid cancer. Additionally, many smaller companies are also involved in the market, offering generic versions of existing drugs or developing new treatments. Overall, the Thyroid Cancer Drugs market is an important part of the pharmaceutical industry, providing treatments that can improve the quality of life for those affected by the disease. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.